GeneDx Q1 2023 pro forma revenue $40.7M (+7% YoY); exome revenue up 22% to $22.4M; reaffirms FY guidance

GeneDx Holdings Corp.

2023-Q1 EPS reported -$3.04 revenue$43,139,000

Pro forma revenue from continuing ops $40.7M, up 7% YoY; whole exome/genome test revenue $22.4M, up 22%.
Adjusted gross margin from continuing ops 34%; total company cash burn improved 31% YoY to $58.8M.
Net loss ($60.4)M; adjusted net loss ($48.9)M, improvement of 23% YoY.
Reaffirms FY2023 guidance: revenue $205-220M, cash burn $95-110M for continuing ops, profitable in 2025.
Completed $150M public offering; appointed Devin K. Schaffer as General Counsel.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GeneDx Holdings Corp. reported the first quarter of 2023 results: revenue $40.7 million. Guidance reaffirmed.

Period: the first quarter of 2023
Revenue: $40.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

GeneDx Reports First Quarter 2023 Financial Results and Business Highlights Generated $40.7 million in first quarter 2023 pro forma revenue from continuing operations, representing a 7% increase year over year

View on SEC.gov

Browse all earnings releases →

GeneDx Holdings Corp. filing history →

Source: SEC EDGAR

accession 0001818331-23-000041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.